Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2018 16:05 ET | Source: REGENXBIO Inc.

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., March 07, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene...
March 06, 2018 16:01 ET | Source: REGENXBIO Inc.

REGENXBIO Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights

Completed dosing of third cohort in RGX-314 Phase I clinical trial for wet AMDContinuing dosing of second cohort in RGX-501 Phase I/II clinical trial for HoFHAnticipate presenting topline data from...
February 27, 2018 16:05 ET | Source: REGENXBIO Inc.

REGENXBIO to Host Conference Call on March 6 to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., Feb. 27, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...
February 08, 2018 16:05 ET | Source: REGENXBIO Inc.

REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD

Clinical trial evaluates one-time treatment for wet AMD using NAV® AAV8 gene therapy18 patients have been dosed at leading retinal surgery centers in the United StatesAnticipate reporting topline data...
February 07, 2018 16:05 ET | Source: REGENXBIO Inc.

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Feb. 07, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...
January 23, 2018 16:10 ET | Source: REGENXBIO Inc.

REGENXBIO Enhances Gene Therapy Manufacturing Capabilities by Entering into Strategic Partnership with FUJIFILM Diosynth Biotechnologies

- REGENXBIO has established internal capability to produce NAV AAV across multiple platforms and at scale of up to 200L - Agreement with FUJIFILM secures access to dedicated cGMP suite capacity...
January 08, 2018 08:00 ET | Source: REGENXBIO Inc.

REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy

AveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMAAmended agreement permits assignment by AveXis upon a change of control without REGENXBIO’s...
January 04, 2018 16:05 ET | Source: REGENXBIO Inc.

REGENXBIO Provides Year-End 2017 Corporate Update

- Initiated third cohort dosing of RGX-314 Phase I clinical trial for wet AMD - - Initiated second cohort dosing of RGX-501 Phase I/II clinical trial for HoFH - - Anticipate completing dosing and...
December 19, 2017 07:00 ET | Source: REGENXBIO Inc.

REGENXBIO Announces IND Active for Phase I/II Trial of RGX-121 to Treat Mucopolysaccharidosis Type II

Novel, one-time, direct-to-CNS treatment for MPS II focused toward potentially preventing the progression of cognitive deficitsClinical trial expected to enroll children with MPS IIAnticipate...
November 22, 2017 07:00 ET | Source: REGENXBIO Inc.

REGENXBIO to Present at Upcoming Investor Conferences

ROCKVILLE, Md., Nov. 22, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...